ArticleBMC pulmonary medicine2026
Study protocol: a 52-week, multicentre, observational, prospective study on the use of a smart platform connected to a single-inhaler triple therapy (ICS/LABA/LAMA) to evaluate effectiveness on treatment adherence and inhaler technique in patients with poorly controlled asthma.
Article in BMC pulmonary medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06908421 (A 52-week, Multicentre, Observational, Prospective Study on the Use of a Smart Platform Connected to a Single-inhaler Triple Therapy), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A 52-week, Multicentre, Observational, Prospective Study on the Use of a Smart Platform Connected to a Single-inhaler Triple Therapy (ICS/LABA/LAMA) to Evaluate Effectiveness on Treatment Adherence and Inhaler Technique in Patients With Poorly Controlled Asthma.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundGood adherence to controller medication and correct inhaler technique is essential for effective asthma management. However, many patients struggle with these aspects, leading to poor symptom control and a higher risk of exacerbations. This study (SiASMARTer) aims to evaluate the impact of the SiA®SMARTer platform - a digital smart platform consisting of an app and an add-on module connected to a pressurized metered-dose inhaler delivering triple therapy (ICS/LABA/LAMA) - on improving adherence and inhaler technique in patients with poorly managed inflammation in asthma (defined as fractional exhaled nitric oxide [FeNO] > 25 ppb).
methodsThis observational study will enrol 60 patients from two sites in Denmark. At baseline, participants will begin using the SiA®SMARTer platform, which includes, on the patient side a smart inhaler cap, a patient app and on the physician side a dashboard. The primary endpoint, with follow-up at 12 and 52 weeks, is the platform's effect on FeNO levels. Secondary endpoints will include changes from baseline in treatment adherence and inhaler technique scores, Asthma Control Test scores, Mini Asthma Quality of Life Questionnaire scores, lung function parameters, FeNO category distribution, exacerbation rates, short-acting β2-agonist use, and patient-reported satisfaction with the SiA®SMARTer platform. Data on adherence and inhaler technique will be continuously collected through the SiA DISCUSSION: This study may offer valuable insights into whether a digital platform can enhance adherence and inhaler technique, and by that improve asthma control. Additionally, it may help discriminate patients requiring therapy escalation from those with poor control due to non-adherence or incorrect inhaler technique.
trial registrationClinicalTrials.gov identifier: NCT06908421, Registration date: 2025-03-26.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.